Value proposition

Exploring novel bacterial glycopeptide antigens to address unmet needs in vaccine development

GlyProVac has via its proprietary platform technology, BEMAP, discovered that 1) O-linked protein glycosylation is a surprisingly abundant post translational modification in bacterial, 2) glycoproteins are linked to increased immunogenicity.
GlyProVac aim to be the first to explore and exploit this novel class of antigens as candidates for vaccine development. The GlyProVac lead YghJ/SslE/AcfD is a conserved protein with a known biological function and has vaccine potential not only in ETEC but also in UPEC. Using BEMAP, GlyProVac has identified 59 glycosylated residues in YghJ. We are in the PoC phase and currently work to establish that glycosylated YghJ elicit a more protective immune response compared to the non-glycosylated version.

Mass Spectrometry, Microbiology, Molecular Biology, and Bacterial Pathogens